Navigation Links
San Antonio Investigators Report on Mountain Cedar Allergy Model
Date:7/25/2013

San Antonio, TX (PRWEB) July 25, 2013

In the July 2013 issue of the Annals of Allergy, Asthma and Immunology, investigators in San Antonio, Texas describe the use of the mountain cedar season as a valuable tool for the assessment of new allergy medications and vaccines. The article, entitled "The mountain cedar model in clinical trials of seasonal allergic rhinoconjunctivitis," discusses the immune features of the pollen, reviews published studies and presents the daily pollen grain counts recorded over 18 years.

Dr. Charles Andrews, a Principal Investigator of the Biogenics Research Chamber and the lead author of the article notes that, “the mountain cedar pollen tsunami hits south-central Texas annually with a ferocity and dependability that have made the season a mainstay in allergy research.”

Thirty-eight studies from the scientific literature are presented, recognizing that many other studies, particularly generic drug trials, are unpublished. Analysis of the pollen counts provided by Dr. Paul Ratner reveals uniformity over many years that allows advance planning for successful natural season trials. Mountain cedar pollen has also been found to elicit major nasal and eye symptoms in multiple studies in the Biogenics Research Chamber. Utilizing mountain cedar pollen in the chamber model provides controlled trials for the evaluation of medications and vaccines, as well as allowing study of the basic inflammatory mechanisms of acute allergic reactions.

About the Company:

Biogenics Research Chamber located in San Antonio, Texas is the only large permanent pollen exposure testing facility in the United States. Dr. Robert Jacobs, Dr. Daniel Ramirez and Dr. Charles Andrews are the owners and Principal Investigators. The facility has a large chamber capable of testing up to 60 allergic participants at a time and a moderate sized chamber for testing up to 32 subjects. Both chambers utilize unique engineering and pollen delivery systems. Two additional chambers are being constructed. Compared to natural season allergy studies, the chambers offer controlled conditions without pollen concentration variation and weather interruptions. Proof of concept, dose-ranging, and onset of action studies are performed for pharmaceutical and vaccine trials. In addition to commercial studies, the Biogenics Research Chamber has performed multiple academic trials examining the basic mechanisms of allergy.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10958220.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Texas Fertility Center Opens New Fertility Clinic in San Antonio
2. Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
3. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
4. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
5. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
6. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
7. Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2013
8. Aratana Therapeutics to Report Second Quarter 2013 Financial Results
9. Global Printed and Flexible Sensors 2013 Report: Forecasts, Players, Opportunities
10. China Pharmaceutical Industry Examined in New Kelly Scientific Publications Report Available at MarketPublishers.com
11. Global Activated Carbon Market 2012-2016: Latest Market Share, Growth, Analysis, Size, Trends & Forecast Research Report 2012-2016 Available at Marketresearchreports.biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):